AbbVie 10-Q, filed Nov 3, 2026

Summary

AbbVie reported $49.4 billion in worldwide net revenues for the nine months ended September 30, 2026, up 11% on a reported basis, with operating earnings of $16.7 billion and diluted earnings per share of $4.79. The company also described regulatory and pipeline developments, including a U.S. court vacating CMS's selection of Botox for Medicare drug price negotiation and multiple approvals or trial results for Skyrizi, Rinvoq, Juvmo, and other medicines.

Key points

• AbbVie reported worldwide net revenues of $49.4 billion for the nine months ended September 30, 2026, up 11% on a reported basis and 10% on a constant currency basis; operating earnings were $16.7 billion, diluted earnings per share were $4.79, and cash flows from operations were $14.9 billion.
• AbbVie announced a voluntary agreement with the U.S. government in January 2026 to provide low prices in Medicaid and expand affordable direct-to-patient offerings, and pledged $100 billion in U.S.-based research and development and capital investments over the next decade; the U.S. government agreed to a three-year exemption from tariffs and future price mandates.
• On October 29, 2026, the U.S. District Court for the District of Columbia vacated and set aside CMS's selection of Botox for the Medicare Drug Price Negotiation Program and enjoined CMS from publishing a maximum fair price for Botox; the ruling is subject to appeal.
• In October 2026, the FDA approved Skyrizi for subcutaneous induction in adults with moderately to severely active Crohn's disease, and in September 2026 the FDA approved Juvmo (tavapadon) for adults with Parkinson's disease.

Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.